Urothelial Carcinoma
Urothelial Carcinoma
Advertisement
Jessica GangaMuscle Invasive Urothelial Carcinoma | May 8, 2025
Researchers find promise for ctDNA-guided immunotherapy for patients with MIBC who underwent radical cystectomy.
Read More
Sia Daneshmand, MDUrothelial Carcinoma | May 8, 2025
The panel concludes with a discussion on the complexities of interpreting ctDNA positivity in earlier-stage bladder cancer.
Sia Daneshmand, MDUrothelial Carcinoma | May 8, 2025
The panel considers the adoption of bladder-sparing protocols and the potential of biomarkers to guide risk stratification.
Sia Daneshmand, MDUrothelial Carcinoma | May 8, 2025
The panel debates the management of high-grade T1 bladder cancer with lymphovascular invasion and variant histology.
Sia Daneshmand, MDUrothelial Carcinoma | May 8, 2025
The panel pivots to complex considerations in bladder cancer treatment, weighing the promise of IO in BCG-naïve patients.
Sia Daneshmand, MDUrothelial Carcinoma | May 8, 2025
The panel shares how patient lifestyle, bladder symptoms, and other factors influence intravesical therapy selection.
Sia Daneshmand, MDUrothelial Carcinoma | May 8, 2025
The panel explores the challenges of delivering bladder-sparing therapies like gem/doce and TAR-200 in real-world settings.
Sia Daneshmand, MDUrothelial Carcinoma | May 8, 2025
The panel discusses a wave of bladder cancer therapies, including cretostimogene, gem/doce, and AI-driven biomarkers.
David Canes, MDUrothelial Carcinoma | May 7, 2025
Dr. Canes discusses the formation of the WellPrept delivery platform and how it aims to boost patient education.
Mohummad Siddiqui, MDUrothelial Carcinoma | May 5, 2025
Mohummad Siddiqui, MD, discusses his work with the Commission on Cancer and their development on standards of care.
John Sfakianos, MDUrothelial Carcinoma Diagnostics | May 5, 2025
John P. Sfakianos, MD, discusses the history and use of ctDNA in the GU oncology field.
Felix Guerrero-Ramos, MDUrothelial Carcinoma | May 5, 2025
At the AUA 2025 Annual Meeting, Dr. Guerrero-Ramos highlights the first results from Cohort 4 of SunRISe-1.
Neal Shore, MD, FACSUrothelial Carcinoma | May 2, 2025
Results of the CREST study show that sasanlimab plus BCG improves EFS compared with BCG alone in high-risk NMIBC.
Sam Chang, MDUrothelial Carcinoma | May 2, 2025
Drs. Chang and Joyce consider the role that N-803 now plays within the treatment paradigm for BCG-unresponsive bladder CIS.
Sam Chang, MDUrothelial Carcinoma | May 2, 2025
Drs. Chang, Joyce take a look at QUILT-3.032, including complete responses to N-803 plus BCG in BCG-unresponsive bladder CIS.
Sia Daneshmand, MDUrothelial Carcinoma | May 2, 2025
Dr. Daneshmand discusses some of the designs and results of ADVANCED-2, PIVOT-006, ABLE-22, and more.
Alireza Ghoreifi, MDUrothelial Carcinoma | April 30, 2025
Dr. Ghoreifi explains how results suggest feasibility with high rates of pathological downstaging and complete response.
Patrick Gomella, MDNon-Muscle Invasive Urothelial Carcinoma | April 30, 2025
Dr. Gomella and Ambinder provide a comprehensive overview of the growing and changing treatment landscape for NMIBC.
Samuel Gold, MDUrothelial Carcinoma | April 28, 2025
Dr. Samuel Gold shares some perspective on the impact of disease recurrence on HRQoL after radical cystectomy.
John Gore, MD, MSUrothelial Carcinoma | April 28, 2025
Dr. John Gore offers interesting data from the CISTO study, favoring radical cystectomy for recurrent high-grade NMIBC.
Advertisement
Advertisement